Diabetic retinopathy (DR) is one of the complications of diabetes mellitus (DM) that cause most hardship. It is the leading cause of blindness in adults of working age. Diabetic macular edema (DME) is the main cause of poor vision in patients with diabetes. In the past, DME was diagnosed by only ophthalmoscope but now with the help of optical coherence tomography (OCT), it is possible to measure the macular thickness objectively and to follow the DME progression quantitatively. Periodic glycosylated haemoglobin (HbA1c) measurements can reflect the long-term control of hyperglycemia. This cross sectional study, conducted over a year (June 2022 to May 2023) aims to see the relationship of Diabetic Retinopathy with the status of control of diabetes, as intensive glycemic control had been proved to be effective in decreasing and progression of DR in type 1 and type 2 diabetic mellitus as demonstrated by the diabetes control and complication trials and the United Kingdom Prospective Diabetic study. Various parameters, including Age distribution of patients, Duration of Diabetes, Presenting and Associated symptoms, Treatment Profile of Patients, Personal Habits, Grade of retinopathy, HbA1c levels and the foveal thickness, were assessed. Results revealed higher HbA1c levels were significantly associated with the development of CSME in patients with diabetic retinopathy p value showing 0.0048. The study highlights the importance of periodic evaluation of glycemic control with routine glycosylated haemoglobin measurements may help optimise visual outcome in diabetic subjects.